UNSPSC 51142571: Rotigotine hydrochloride

This classification denotes a dopamine agonist with the molecular formula C19H25NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q1W9573L2, chemically known as rotigotine hydrochloride, (-)-, but more generally known as rotigotine hydrochloride, which bears US NIH Compound Identifier 180335. European Medicines Agency schedules rotigotine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21254.

Most nations, for tariff purposes, schedule rotigotine hydrochloride under HS 29349990. SMILES: CCCN(CCC1CCCS1)[C@H]2CCC3C(CCCC3O)C2.CL.

UNSPSC 51142571 Rotigotine hydrochloride is a Commodity code that nominally designates a specific pharmaceutical active ingredient, yet recent state and local solicitations tagged under this code show no activity purchasing rotigotine itself. Instead, the three most recent opportunities posted under this code involve broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. The mismatch between the code's narrow pharmaceutical designation and the actual scope of work being solicited suggests either misclassification in source data or that procurement systems are using this code as a proxy for pharmaceutical purchasing more broadly. The issuing bodies span a county public-health agency (Seminole County, Florida), a state health and human services commission (Texas HHS), and a multistate cooperative purchasing alliance (Minnesota MMCAP serving multiple state and local entities including Oregon).

The most recent activity concentrates in the South and Upper Midwest. Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 — note that this deadline date appears historical and may indicate outdated posting information. Texas HHS issued a Request for Information on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, designed as foundational market research before formal RFP release. Minnesota MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026; this cooperative vehicle includes participating entities across Minnesota and Oregon. The MMCAP solicitation specifies mandatory distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson), requires cGMP and Drug Supply Chain Security Act certification, and evaluates proposals weighted heavily toward price competitiveness (75 percent). The code shows minimal relevant recent activity — these three opportunities do not consistently align with rotigotine-specific purchasing.